Physician profile
Clovis Raymond
NPI 1902034051
$7,012.05
in general payments reported to CMS, 2019-2025
22 companies · $2,779 in 2025
The $2,779 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $148 · 2021: $768 · 2022: $629 · 2023: $1,186 · 2024: $1,371 · 2025: $2,779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,230 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,229.51 |
| Education | $106.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,377.60 | 2021-2025 | |
| Alkermes, INC. | $806.25 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $781.85 | 2024-2025 | Invega Sustenna, Spravato |
| E.R. Squibb & Sons, L.L.C. | $664.78 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $387.04 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Lundbeck LLC | $355.47 | 2021-2025 | Abilify Maintena, Rexulti |
| Allergan, INC. | $222.78 | 2019-2020 | |
| Axsome Therapeutics, INC. | $216.88 | 2024-2025 | Auvelity |
| Adlon Therapeutics L.P. | $176.40 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $175.93 | 2023-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $159.03 | 2022-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $144.94 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.63 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $124.99 | 2025 | Uzedy |
| Collegium Pharmaceutical, INC. | $70.73 | 2025 | Jornay Pm |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $50.26 | 2022-2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $47.81 | 2024 | Quviviq |
| Luye Pharma (USA) LTD. | $40.54 | 2025 | Erzofri Extended-Release |
| Indivior INC. | $31.64 | 2022-2023 | Perseris |
| Orexo US, INC. | $16.26 | 2022 | |
| Tris Pharma INC | $14.93 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clovis Raymond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.